Trials
Search / Trial NCT05661916

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Launched by ALNYLAM PHARMACEUTICALS · Dec 15, 2022

Trial Information

Current as of January 22, 2025

Recruiting

Keywords

Attr Amyloidosis Si Rna

ClinConnect Summary

This clinical trial is studying a new treatment called ALN-TTRSC04, which is being tested for its safety and how well it works in healthy volunteers. The main goal is to find out how the body handles this treatment and to see if it's safe to use. The trial is currently looking for participants aged between 18 and 75 years, and anyone interested must have a body mass index (BMI) within a specific range (between 18.0 and 30.0).

Participants in this trial will receive single doses of the treatment and will be monitored closely to check for any side effects or reactions. It's important to note that individuals with certain health conditions, like kidney issues or elevated liver enzymes, will not be eligible to participate. If you or someone you know fits the eligibility criteria and is looking for new treatment options, this could be an opportunity to contribute to research in this area.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening.
  • Exclusion Criteria:
  • Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening.
  • Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin above the upper limit of normal (ULN).

Trial Officials

Medical Director

Study Director

Alnylam Pharmaceuticals Inc

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on the development of innovative therapies based on RNA interference (RNAi) technology. Founded in 2002, Alnylam is dedicated to transforming the treatment landscape for patients with genetically defined diseases by leveraging its proprietary platform to discover and develop novel therapeutics. With a robust pipeline of clinical programs targeting a range of conditions, including rare genetic disorders and prevalent diseases, Alnylam is committed to advancing scientific research and improving patient outcomes through cutting-edge medicine and rigorous clinical trials. The company emphasizes collaboration and transparency in its operations, fostering partnerships within the scientific community to drive innovation and enhance healthcare solutions globally.

Locations

London, , United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials